BDX
NYSE · Health Care
Becton Dickinson And Co
$183.00
+2.30 (+1.27%)
BDX News5 articles
BDX Jumps as Free Cash Flow Surges 44.6%, Full-Year EPS Guidance Raised
Becton Dickinson shares climbed after fiscal Q3 results topped expectations and free cash flow surged 44.6% for the nine-month period, prompting a slight raise to the full-year profit outlook.
Hologic $18.3B Take-Private Finalized, CEO Exits as Stock Leaves S&P 500
Hologic has received all required approvals for its $18.3 billion acquisition by Blackstone and TPG, with the deal closing around April 7. CEO Steve MacMillan will retire upon completion.
BDX Surges 5% After Revising Long-Term Profit Outlook
Becton Dickinson shares rallied sharply in extended trading after the company updated its 2026 earnings forecast. Investors weighed margin pressures against a solid quarterly performance.
BD Revises 2026 Outlook Following Waters Spin-Off, Shares Dip
Becton Dickinson shares declined after the company lowered its 2026 profit forecast following the completion of its Biosciences unit spin-off to Waters Corporation.
Thermo Fisher Shares End Week Lower Amid Research Funding Concerns
Thermo Fisher Scientific closed Friday at $542.83, down 6.7% for the week as investors weigh pressure from academic research funding cuts. The company's 2026 outlook projects adjusted earnings of $24.22 to $24.80 per share.